Our Vision

We are spearheading treatments that use the immune system to eliminate cancer, without chemotherapy or radiation. Our goal is to render today’s therapies obsolete until treating childhood cancer is no different than treating an everyday virus.

Accelerating Progress Toward Cures

  • Goal: Cure Neuroblastoma

    Dr. Julie Park is leading one of the world’s first clinical studies of immunotherapy for neuroblastoma – the deadliest childhood cancer.

  • We Need Your Help

    You can help bring an end to childhood cancer all over the world, by supporting our Strong Against Cancer fundraising initiative.

Participate in Research

Our researchers have started the first round of clinical trials exploring a potential cure.

Help us answer questions about childhood health and illness, and help other children in the future. Learn more.


Developing groundbreaking cancer treatments takes more than just the right ideas. It also takes the right people.

Please visit Seattle Children’s careers page to learn about current openings.

For information about potential opportunities in the Ben Towne Center, email us.

Latest News

Collaborative aims to accelerate immunotherapy development for pediatric cancers – 10.12.2018 – HemOnc Today
Experts from several health systems have launched CureWorks, a collaborative effort to accelerate the development of immunotherapies for children with cancer. Participating institutions include Seattle Children’s, Children’s National Health System, BC Children’s Hospital and Children’s Hospital Los Angeles. Dr. Mike Jensen, executive director of CureWorks and director of Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute, said key components of the collaboration include the expansion of multisite clinical trials for immunotherapies developed by the academic partners, a centralized facility for reprogramming immune cells to recognize and fight cancer, and a network of member hospitals to share resources on the use of CAR T-cell therapy in pediatric populations. HemOnc Today spoke with Jensen about the need for immunotherapies for pediatric cancer populations, the advantages of collaboration and the goals of the initiative.

20 top children’s hospitals in innovation and technology – 9.05.2018 – Parents 
Breakthroughs are born at these 20 children’s hospitals that rose to the top in an exclusive Parents magazine survey. The survey sought to identify hospitals with a proven track-record of medical advances as well as innovative ways to make little patients and their families more comfortable, while also taking into account a hospital’s adoption of the latest technologies and its efforts to share its innovations with other pediatric centers so more kids can benefit. As a member of the St. Baldrick’s Foundation’s Stand Up to Cancer Pediatric Cancer Dream Team, Seattle Children’s Hospital is focused on developing new treatments for many kinds of difficult-to-cure kid cancers. Currently, doctors are working on a vaccine to allow reprogrammed T cells to last longer, hoping to raise success rates. “We’re also studying how to make T cells attack solid tumors like neuroblastoma and brain tumors,” explains Dr. Mike Jensen, director of Seattle’s Ben Towne Center for Childhood Cancer Research.

Seattle Children’s launches into solid tumor treatments with new CAR T immunotherapy trial – 8.07.2018 – GeekWire 
Seattle Children’s Research Institute is launching a CAR T immunotherapy clinical trial that will examine a new kind of cancer-fighting treatment. CAR T therapies have found early success in blood cancers, including leukemia and lymphoma, but have run into obstacles when it comes to solid tumor cancers like lung and breast cancer. This new trial, called STRIvE-01, is hoping to overcome those obstacles for children with sarcoma, kidney and neuroblastoma tumors. The trial will treat children whose cancer has relapsed, a group that often has few remaining treatment options. Dr. Katie Albert, the lead investigator of the trial, said the goal of this early trial is to test the safety of the new therapy and establish the best dose, although researchers also hope to see the trial make headway against patients’ tumors. “Further, we hope to observe efficacy against one or more types of tumors and minimal toxicity to normal tissues. In the best case scenario, this will simply be the first step in developing a curative therapy for our highest risk patients,” Albert said. Scientists at the Ben Towne Center for Childhood Cancer Research will reprogram the T-cells of patients in the trial to create CAR T cells designed to hunt down cancer cells that display the EGFR protein. The new trial is yet another notch in the belt of Seattle Children’s growing immunotherapy research program.